DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes
Add patients with power kidney illness with or without diabetes to the rising list of those who win proven have the benefit of therapy with an SGLT2 inhibitor.
Within the DAPA-CKD trial, therapy with the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga, AstraZeneca) lower the incidence of substantially worsened power kidney illness (CKD) by an moderate of 39% when put next with placebo when added to traditional therapy, with a number desired to treat of 19 to forestall one main result match after a median of two.4 years.
The level of profit was same in both the one-third of enrolled patients without diabetes and in the two-thirds with diabetes, showing a statistically predominant 50% lower in the first endpoint amongst patients without diabetes, Hiddo J.L. Heerspink, MD, reported at the virtual European Society of Cardiology (ESC) 2020 Congress.
“We found that dapagliflozin delayed the initiation of dialysis and diminished the number of deaths,” regardless of diabetes location, Heerspink, from the College Medical Centre Groningen, the Netherlands, said at some stage in a press convention. “The DAPA-CKD trial has proven dapagliflozin’s doable as a lengthy-awaited unique therapy for patients with power kidney illness.”
Silent Era
This finding ushers in a “entirely unique skills in power kidney illness administration,” commented Janani Rangaswami, MD, a nephrologist and cardiorenal syndrome specialist at Einstein Medical Center in Philadelphia, Pennsylvania. “It be correct news” for these patients.
The outcomes confirmed that dapagliflozin is the first “game-altering” drug for CKD in two decades, following the introduction of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers, she said in an interview.
And given the consistency of the findings with the outcomes from several other learn that documented predominant renal security by several different SGLT2 inhibitors, the outcomes from this single trial furthermore convincingly build dapagliflozin as a protracted-established-of-care agent to employ on the types of patients the imagine enrolled, she added.
Representing Many Accurate-world Sufferers
The DAPA-CKD trial enrolled 4304 patients with albuminuria according to having a urinary albumin-to-creatinine ratio of at the least 200 mg/g and an estimated glomerular filtration price (eGFR) of 25 to 75 mL/min per 1.73 m2 (with 90% of patients having an eGFR < 60 mL/min per 1.73 m2), and 97% have been receiving therapy with a renin-angiotensin scheme–blocking drug.
The main endpoint was the mixed price of a drop in eGFR of at the least 50% from baseline, development to complete-stage renal illness, or renal or cardiovascular death; the between-neighborhood incompatibility in this composite was pushed essentially by both preserved eGFR and prevention of cease-stage renal illness.
This represents both a appropriate target population and traumatic endpoints, Rangaswami said. The imagine was “very consultant of who we gaze in proper-world practice,” a neighborhood that seemingly entails “millions” of U.S. patients with nondiabetic CKD, she estimated.
One other basic finding was that 14% of the enrolled patients had eGFR at baseline of 25 to 29 mL/min per 1.73 m2, pegging them as having stage 4 CKD, and the median baseline eGFR was 43 mL/min per 1.73 m2; on the opposite hand, dapagliflozin therapy was as stable and effective in these patients because it was in enrolled patients with a increased level of retained renal exercise.
This skills must give clinicians increased confidence regarding the employ of dapagliflozin and other medication in the SGLT2 inhibitor class in patients with substantially sorrowful renal feature, Rangaswami said.
“We now must be extra proactive about treating patients with extra developed kidney illness who can peaceful profit” from dapagliflozin therapy. “The sooner you intervene the upper,” to slack additional development, nevertheless the unique findings gift “profit even when treating patients with lower eGFRs. There is peaceful hope to forestall or lengthen dialysis.”
A Coronary heart-Kidney Connection
Dapagliflozin therapy furthermore lower all-trigger mortality by a statistically predominant relative 31%, and one other secondary-endpoint prognosis confirmed a statistically predominant 29% relative reduction in the price of cardiovascular death or heart failure hospitalization. This profit was viewed consistently in several prior learn of SGLT2 inhibitors nevertheless per chance was sudden right here because enrolled patients underwent no change for a history of heart failure or every other cardiovascular illness.
However the finding ought to not surprise because “power kidney illness is an honest risk aspect for cardiovascular illness across the board, and seriously for heart failure,” mighty Rangaswami.
“Coronary heart and kidney illness is one sizable spectrum,” and the gathered skills of several trials that have now proven the efficacy of SGLT2 inhibitors amongst patients with heart failure with diminished ejection section or with CKD, regardless of their glycemic adjust, reveals how broadly this drug class can profit patients across the breadth of this spectrum, she said.
DAPA-CKD was funded by AstraZeneca, the corporate that markets dapagliflozin (Farxiga). Dr Heerspink has been a well informed to and received learn funding from AstraZeneca and from several other companies. Dr Rangaswami had no disclosures.
European Society of Cardiology (ESC) Congress 2020. Presented August 30, 2020.
This article will furthermore seem on MDedge.com , fragment of the Medscape Expert Network.